AADI - Why Is Anti-Cancer Focused Aadi Bioscience Stock Trading Lower Today? | Benzinga
Aadi Bioscience Inc (NASDAQ: AADI) shares are trading lower after the company released results from a planned interim analysis on the first third of participants in the ongoing tumor-agnostic PRECISION1 trial of nab-sirolimus in patients with TSC1 or TSC2 inactivating alterations.
The interim analysis includes data from the first third of trial participants (n=40) with a minimum of 4.5 months of follow-up, including investigator-assessed response and safety analyzed separately in each TSC1 and TSC2 arms.
Efficacy of nab-sirolimus in patients with tumors harboring pathogenic inactivating alteration ...